Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7–H4 expression through the MEK/ERK signaling pathway

Zhiming Zhao,Ningyue Zhang,Anqi Li,Bin Zhou,Yali Chen,Shaomu Chen,Moli Huang,Fengying Wu,Liang Zhang
DOI: https://doi.org/10.1016/j.canlet.2020.04.013
IF: 9.756
2020-08-01
Cancer Letters
Abstract:<p>The Insulin-like growth factor-1/Insulin-like growth factor-1 receptor (IGF1/IGF1R) axis contributes to immunosuppression during tumor progression; however, the underlying mechanism remains unclear. In the present study, we found that IGF1 stimulation or IGF1R overexpression (IGF1R-OE) could upregulate the expression of B7–H4, while IGF1R inhibition downregulated B7–H4 in both A549 and SPC-A-1 lung cancer cell lines. IGF1R-OE conferred the inhibition of CD8<sup>+</sup> T cells by cancer cells <em>in vitro</em>, and induction of B7–H4 expression was mediated by the activation of the MEK/ERK1/2 signaling pathway. The <em>in vitro</em> findings were further confirmed <em>in vivo</em> using a Lewis lung cancer mouse model. IGF1R-OE promoted tumor growth and inhibited tumor infiltration by CD8<sup>+</sup> T cells in the mouse model. However, this effect was suppressed when B7–H4 was knocked down in IGF1R-OE cells. Our findings suggest that IGF1R could induce immunosuppression in lung cancer by upregulating the expression of B7–H4 through the MEK/ERK pathway. B7–H4 may therefore be a potential therapeutic target for lung cancer immunotherapy.</p>
oncology
What problem does this paper attempt to address?
The problem this paper attempts to address is: How does the insulin-like growth factor-1 receptor (IGF1R) induce immunosuppression in lung cancer by upregulating B7-H4 expression via the MEK/ERK signaling pathway? Specifically, the study aims to investigate how IGF1R suppresses the function of CD8+ T cells in lung cancer by upregulating B7-H4 expression and whether this process is dependent on the MEK/ERK signaling pathway. The study further explores the potential of B7-H4 as a target for lung cancer immunotherapy. The main findings of the paper include: 1. **Correlation between IGF1R and B7-H4**: Analysis of the TCGA dataset and clinical samples revealed that high expression of IGF1R is associated with a decrease in CD8+ T cells and an increase in B7-H4. 2. **Mechanism of IGF1R upregulating B7-H4**: In lung cancer cell lines, overexpression of IGF1R or IGF1 stimulation can upregulate B7-H4 expression, while inhibition of IGF1R downregulates B7-H4 expression. This process depends on the activation of the MEK/ERK signaling pathway. 3. **Role of B7-H4 in IGF1R-mediated CD8+ T cell suppression**: Knockdown of B7-H4 expression can reverse the suppression of CD8+ T cell function caused by IGF1R overexpression. 4. **In vivo experimental validation**: In mouse models, overexpression of IGF1R promotes tumor growth and inhibits CD8+ T cell infiltration, while knockdown of B7-H4 can inhibit tumor growth and restore CD8+ T cell function. These findings suggest that IGF1R induces immunosuppression in lung cancer by upregulating B7-H4 expression via the MEK/ERK signaling pathway, and B7-H4 may be a potential target for lung cancer immunotherapy.